Giovanni Luca Scaglione

10PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer geneticsMedical molecular engineering of nucleic acids and proteinsAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 19, 2025
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.

Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino

|May 28, 2025
Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment.

Giovanni Luca Scaglione, Valentina Lombardo, Maurizio Polano

|Jan 08, 2025
Identification of the novel BRCA1 c.2463_2464delTA mutation in two high grade serous ovarian cancer sisters and potential dosage effects implications: a case report.

Valentina Lombardo, Giuseppa Scandurra, Angela Pettinato

|Nov 27, 2024
Broadening the PHIP-Associated Neurodevelopmental Phenotype.

Giulia Pascolini, Giovanni Luca Scaglione, Balasubramanian Chandramouli

|Sep 28, 2024
COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.

Anna Pira, Feliciana Mariotti, Francesco Moro

|Dec 09, 2023
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.

Giovanni L Scaglione, Sandro Pignata, Angela Pettinato

Pageof 2

Frequent Collaborators

3 joint publications

Valentina Lombardo

3 joint publications

Paolo Scollo

3 joint publications

Cristina Albanesi

3 joint publications

Stefania Madonna